medigraphic.com
ISSN 0016-3813 (Impreso)

2015, Número 6

<< Anterior Siguiente >>

Gac Med Mex 2015; 151 (6)


Actualidades en farmacodermias severas: síndrome de Stevens-Johnson (SSJ) y necrólisis epidérmica tóxica (NET)

Martínez-Cabriales SA, Gómez-Flores M, Ocampo-Candiani J

Idioma: Español
Referencias bibliográficas: 115
Paginas: 777-787
Archivo PDF: 513.22 Kb.


RESUMEN

El SSJ y la NET son enfermedades cutáneas severas con una alta morbilidad y mortalidad. Forman parte de un espectro de dermatitis reaccional y se distinguen por la extensión de piel afectada. La mayoría de los casos son consecuencia de la ingesta de medicamentos, pero la fisiopatología no está bien dilucidada. Se considera que en su patogénesis intervienen la granulisina, la vía de señalización del Fas y numerosas citocinas proinflamatorias. El diagnóstico requiere una correlación clinicohistopatológica y el tratamiento, la suspensión temprana del fármaco causal, junto con un tratamiento de soporte. En el presente artículo se revisan actualidades en la patogénesis, el diagnóstico y el tratamiento de estas enfermedades.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256(24):3358-63.

  2. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-9.

  3. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011;127(3 Suppl):S60-6.

  4. Vassallo C, Derlino F, Brazzelli V, D’Ospina RD, Borroni G. Acute generalized exanthematous pustulosis: report of five cases and systematic review of clinical and histopathological findings. G Ital Dermatol Venereol. 2014;149(3):281-90.

  5. Stevens A JF. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child. 1992;24:526.

  6. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68:355-61.

  7. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5):539-43.

  8. Mockenhaupt M, Schopf E. Epidemiology of drug-induced severe skin reactions. Semin Cutan Med Surg. 1996;15(4):236-43.

  9. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.

  10. Stevens D, Swift PG, Johnston PG, Kearney PJ, Corner BD, Burman D. Mycoplasma pneumoniae infections in children. Archives of disease in childhood. 1978;53(1):38-42.

  11. Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau JC. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin MicrobiolI Infect Dis. 1995;14(6):558-9.

  12. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25-32.

  13. Lin YF, Yang CH, Sindy H, et al. Severe cutaneous adverse reactions related to systemic antibiotics. ClinI Infect Dis. 2014;58(10):1377-85.

  14. Fernandez FA, Pintor E, Quesada R, Garces FJ. [Toxic epidermal necrolysis induced by phenytoin and whole brain radiotherapy]. Actas Dermosifiliogr. 2007;98(7):483-5.

  15. Sanz-Munoz C, Martinez-Moran C, Torrero-Anton MV, Miranda-Romero A. [Indapamide-associated Stevens-Johnson syndrome]. Actas Dermosifiliogr. 2008;99(4):321-2.

  16. Khafaga YM, Jamshed A, Allam AA, et al. Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy. Acta Oncol. 1999;38(1):111-6.

  17. Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2010;11(7):973-87.

  18. Blanes M, Belinchon I, Portilla J. [Cutaneous drug reactions in HIV-infected patients in the HAART era]. Actas Dermosifiliogr. 2009;100(4):253-65.

  19. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324(6):377-84.

  20. Sotelo-Cruz N. [Stevens-Johnson syndrome and toxic epidermal necrolysis in children]. Gac Med Mex. 2012;148(3):265-75.

  21. Ardern-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol. 2011;71(5):672-83.

  22. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134-9.

  23. Chung WH, Hung SI. Genetic markers and danger signals in stevens- johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010;59(4):325-32.

  24. Choi HJ, Ku JK, Kim MY, et al. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption. Br J Dermatol. 2006;154(3):419-25.

  25. Viard-Leveugle I, Gaide O, Jankovic D, et al. TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2013;133(2):489-98.

  26. Henkart PA. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity. 1994;1(5):343-6.

  27. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683-93.

  28. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol. 2004; 123(5):850-5.

  29. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343-50.

  30. Guillaume JC, Roujeau JC, Revuz J, Penso D, Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell’s syndrome). Arch Dermatol. 1987;123(9):1166-70.

  31. Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012;66(6):995-1003.

  32. Bolognia J JJ, Rapini R. Drug reactions. Dermatology. 2008;1.

  33. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-85.

  34. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens- Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-6.

  35. Arndt KA, Feingold DS. The sign of Pyotr Vasilyewich Nikolsky. N Engl J Med. 1970;282(20):1154-5.

  36. Wilkins J, Morrison L, White CR, Jr. Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Clin. 1992;10(3):571-82.

  37. Becker DS. Toxic epidermal necrolysis. Lancet. 1998;351(9113):1417-20.

  38. Hung CC, Liu WC, Kuo MC, Lee CH, Hwang SJ, Chen HC. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol. 2009;29(6):633-8.

  39. Blum L, Chosidow O, Rostoker G, Philippon C, Revuz J, Roujeau JC. Renal involvement in toxic epidermal necrolysis. J Am Acad Dermatol. 1996;34(6):1088-90.

  40. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23(12):1237-44.

  41. Wallis C, McClymont W. Toxic epidermal necrolysis with adult respiratory distress syndrome. Anaesthesia. 1995;50(9):801-3.

  42. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160-5.

  43. Goens J, Song M, Fondu P, Blum D, Achten G. Haematological disturbances and immune mechanisms in toxic epidermal necrolysis. Br J Dermatol. 1986;114(2):255-9.

  44. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-53.

  45. Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011;32(2):237-45.

  46. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126(2):272-6.

  47. Finkelstein Y, Macdonald EM, Li P, Hutson JR, Juurlink DN. Recurrence and mortality following severe cutaneous adverse reactions. JAMA. 2014;311(21):2231-2.

  48. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens- Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet. 1999;353(9171):2190-4.

  49. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114(5):1209-15.

  50. Paquet P, Jacob E, Damas P, Pierard GE. Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell’s syndrome) after putative beta-lactam cross-reactivity: Case report and scrutiny of antibiotic imputability. Crit Care Med. 2002;30(11):2580-3.

  51. Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135(1):6-11.

  52. Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med. 2009;151(7):514-5.

  53. Nagasawa M, Isoda T, Itoh S, et al. Analysis of serum granulysin in patients with hematopoietic stem-cell transplantation: its usefulness as a marker of graft-versus-host reaction. Am J Hematol. 2006;81(5):340-8.

  54. Fujita Y, Yoshioka N, Abe R, et al. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2011;65(1):65-8.

  55. Nakajima S, Watanabe H, Tohyama M, et al. High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol. 2011;147(9):1110-2.

  56. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 2007;220:35-46.

  57. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Ann RevI Immunol. 2010;28:367-88.

  58. Wittwer C, Boeck S, Heinemann V, et al. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer. 2013;133(11):2619-30.

  59. Xiao J, Ding Y, Huang J, et al. The association of HMGB1 gene with the prognosis of HCC. PloS one. 2014;9(2):e89097.

  60. Chen Z, Liew D, Kwan P. Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions. PloS one. 2014;9(5):e96990.

  61. Ferrell PB, Jr., McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543-6.

  62. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019-24.

  63. Watanabe R, Watanabe H, Sotozono C, Kokaze A, Iijima M. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Eur J Dermatol. 2011;21(6):889-94.

  64. Iwai S, Sueki H, Watanabe H, Sasaki Y, Suzuki T, Iijima M. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically. J Dermatol. 2012;39(9):781-6.

  65. Cho YT, Lin JW, Chen YC, et al. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol. 2014;70(3):539-48.

  66. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323-7.

  67. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439-44.

  68. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-8.

  69. Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555-62.

  70. Barbaud A, Reichert-Penetrat S, Trechot P, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998;139(1):49-58.

  71. Lin YT, Chang YC, Hui RC, et al. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol. 2013;27(3):356-64.

  72. Harr T, French LE. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens- Johnson syndrome. Med Clin North Am. 2010;94(4):727-42, x.

  73. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens- Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J. 2002;8(1):5.

  74. Araki Y, Sotozono C, Inatomi T, et al. Successful treatment of Stevens- Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol. 2009;147(6):1004-11, 1011.e1.

  75. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens- Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144-8.

  76. Roujeau JC. Treatment of severe drug eruptions. J Dermatol. 1999;26(11): 718-22.

  77. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol. 1991;25(5 Pt 1):778-86.

  78. Sakellariou G, Koukoudis P, Karpouzas J, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs. 1991;14(10):634-8.

  79. Yamada H, Takamori K. Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan. Ther Apher Dial. 2008;12(5):355-9.

  80. Szczeklik W, Nowak I, Seczynska B, Sega A, Krolikowski W, Musial J. Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis. Ther Apher Dial. 2010;14(3):354-7.

  81. Narita YM, Hirahara K, Mizukawa Y, Kano Y, Shiohara T. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol. 2011;38(3):236-45.

  82. Chaidemenos GC, Chrysomallis F, Sombolos K, Mourellou O, Ioannides D, Papakonstantinou M. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36(3):218-21.

  83. Kostal M, Blaha M, Lanska M, et al. Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases. J Clin Apher. 2012;27(4):215-20.

  84. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48(3):473-8.

  85. Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol. 2013;79(5):686-92.

  86. Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847-53.

  87. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490-3.

  88. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367(21):2015-25.

  89. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87(3):206-18.

  90. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139(1):33-6.

  91. Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol. 2010;20(6):743-7.

  92. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58(1):33-40.

  93. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012;167(2):424-32.

  94. Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol. 2013;169(6):1304-9.

  95. Yang Y, Xu J, Li F, Zhu X. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol. 2009;48(10):1122-8.

  96. Patmanidis K, Sidiras A, Dolianitis K, et al. Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: successful treatment of an elderly patient. Case Rep Dermatol Med. 2012;2012:915314.

  97. Gaitanis G, Spyridonos P, Patmanidis K, et al. Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin. Dermatology. 2012;224(2):134-9.

  98. Velez A, Moreno JC. Toxic epidermal necrolysis treated with N-acetylcysteine. J Am Acad Dermatol. 2002;46(3):469-70.

  99. Redondo P, de Felipe I, de la Pena A, Aramendia JM, Vanaclocha V. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol. 1997;136(4):645-6.

  100. Paquet P, Jennes S, Rousseau AF, Libon F, Delvenne P, Pierard GE. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns. 2014;40(8):1707-12.

  101. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor- alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002;146(4):707-9.

  102. Wojtkiewicz A, Wysocki M, Fortuna J, Chrupek M, Matczuk M, Koltan A. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol. 2008;88(4):420-1.

  103. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol. 2005;116(4):923-4.

  104. Al-Shouli S, Abouchala N, Bogusz MJ, Al Tufail M, Thestrup-Pedersen K. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol. 2005;85(6):534-5.

  105. Kreft B, Wohlrab J, Bramsiepe I, Eismann R, Winkler M, Marsch WC. Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab. J Dermatol. 2010;37(10):904-6.

  106. Famularo G, Di Dona B, Canzona F, Girardelli CR, Cruciani G. Etanercept for toxic epidermal necrolysis. Ann Pharmacother. 2007;41(6): 1083-4.

  107. Gubinelli E, Canzona F, Tonanzi T, Raskovic D, Didona B. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009 36(3):150-3.

  108. Scott-Lang V, Tidman M, McKay D. Toxic epidermal necrolysis in a child successfully treated with infliximab. Pediatr Dermatol. 2014;31(4):532-4.

  109. Zarate-Correa LC, Carrillo-Gomez DC, Ramirez-Escobar AF, Serrano- Reyes C. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol. 2013;23(1):61-3.

  110. Worsnop F, Wee J, Natkunarajah J, Moosa Y, Marsden R. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus. Clin Exp Dermatol. 2012;37(8):879-81.

  111. Paquet P, Paquet F, Al Saleh W, Reper P, Vanderkelen A, Pierard GE. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol. 2000;22(5):413-7.

  112. Napolitano M, Giampetruzzi AR, Didona D, Papi M, Didona B. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases. J Am Acad Dermatol. 2013;69(6):e303-5.

  113. Redondo P, Ruiz de Erenchun F, Iglesias ME, Monedero P, Quintanilla E. Toxic epidermal necrolysis. Treatment with pentoxifylline. Br J Dermatol. 1994;130(5):688-9.

  114. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998; 352(9140):1586-9.

  115. Nagata S. Apoptosis by death factor. Cell. 1997;88(3):355-65.




2020     |     www.medigraphic.com